PARC’s concepts for trusted systems and digital property rights led to the joint venture called ContentGuard. This DRM software offers content owners greater control and flexibility over the distribution of their material. To enable authorization of content access in a universal language, PARC, which is now part of SRI, develops eXtensible rights Markup Language (XrML).
SRI researchers study the cells of the long-living rodent to find new drug targets for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders.
SRI scientists are developing a cell-based platform using an often-undervalued subset of helper T cells to deliver potent antitumor proteins for solid tumors, overcoming dose-related toxicities.
Ravenswood delivers high-fidelity training experiences to improve military readiness and performance.